← Leaderboards
Andrew Mizisin
Winsantor, Inc.
$2,779,181
Attributed
$3,012,391
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–20$2M$1.5M$1M$500K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$3,012,391 · 4
By mechanism
R42$1,997,420 · 1
R41$764,971 · 2
SB1$250,000 · 1
Top collaborators
- Jerel Adam Fields1 shared
Others in their field
Other Emerging Leaders on “Nerve”
- Susan Abushakra · Alzheon, Inc.$50,765,244
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$27,307,774
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$22,748,761
- Alan D. Palkowitz · Indiana University Indianapolis$20,904,013
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
Research focus
NerveMitochondrial DysfunctionNeuronsMitochondriaPirenzepinePreventSmall Business Technology Transfer ResearchCholinergicGrowthNeuropathyPeripheral Nervous System DiseasesMuscarinic Acetylcholine ReceptorPeripheralIn VivoReceptorChemotherapy-Induced Peripheral NeuropathyNeuritesPainful NeuropathyDoseCancer PatientEnergy SupplyIndexingFiberPathogenesis
Grant awards (5)
Submission of Investigational New Drug application to the Federal Drug Administration to support clinical development of topical pirenzepine for CIPN.$250,000
SB1 · FY2020 · CA · contact PI
Development of Pirenzepine for CIPN$1,373,465
R42 · FY2019 · CA · contact PI
Development of Pirenzepine for CIPN$623,955
R42 · FY2018 · CA · contact PI
Development of Pirenzepine for HIV-SN$466,421
R41 · FY2017 · NS · contact PI
Development of Pirenzepine for CIPN$298,550
R41 · FY2017 · CA · contact PI